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tion and improvement in physiologic status
may be achieved to improve survival follow-
ing the transplant.3
A possible scoring system for better se-
lection of patient criteria is sought. In this
context the Acute Physiology and Chronic
Health Evaluation II (APACHE II) scoring
system, a multiparameter, physiology-based
predictor of outcome, might be helpful. It can
aid in both selection and timing of LVAD
implantation, particularly in patients not
meeting normal hemodynamic criteria for
LVAD usage.4
Development of right ventricular failure
often causes poor results in patients with
LVADs. It is important to take into consid-
eration the predictive factors including the
need for circulatory support, female gender,
and nonischemic etiology, along with the he-
modynamic alterations including low pulmo-
nary artery pressure and low right ventricle
stroke work index, that might indicate poor
right ventricular outcome.5 Careful observa-
tion of the above would assist both in pa-
tient selection and clinical handling of
isolated LVAD implants.
Omer Ashraf, MBBS
Aga Khan University
Karachi, Pakistan
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Reply to the Editor:
We thank Dr Ashraf for his comments on
our recent article concerning the use of left
ventricular assist devices (LVADs) in pa-
tients with chronic congestive heart fail-
ure.1 His letter invites us to discuss several
important points.
First, to clarify the device type used pre-
dominantly at our center and used exclu-
sively in our study, we favor the HeartMate
XVE (single-lead vented electric) LVAD
(Thoratec Corp, Pleasanton, CA) for its rela-
tive ease of implantation, durability, and lack
of need for systemic anticoagulation. Our
long-term experience with this device has
paralleled an evolution in design, resulting in
improved bridge-to-transplant and posttrans-
plant survival rates.2
Next, we could not agree more with Dr
Ashraf’s observation that the timing of
transplantation following LVAD insertion
plays a critical role in determining survival.
Our own unpublished data show near nor-
malization of blood urea nitrogen, creatinine,
and liver function values at approximately 3
months of support time, bolstering the con-
cept of enhanced end-organ perfusion by the
LVAD. Moreover, the smooth transition to
cardiac rehabilitation and nutritional optimi-
zation throughout the recovery period are of
critical importance.
Although we do not employ the Acute
Physiology and Chronic Health Evaluation
II (APACHE II) scoring system ourselves,
we use similar clinical and laboratory-
based parameters to select LVAD candi-
dates. All patients referred for LVAD are
generally refractory to maximal medical ther-
apy, which often includes the use of intrave-
nous inotropes, vasopressors, and intra-aortic
balloon pumps. Exclusion is therefore done
on the basis of such factors as ventilatory
status, elevated pulmonary pressures, and pro-
longed prothrombin time.
Despite the physiologic benefits of LVADs,
even as they apply to the right ventricle,
right heart failure (RHF) occurs in approx-
imately 15% to 20% of patients postoper-
atively.3,4 Multiple studies have sought to
identify demographic and hemodynamic risk
factors predictive of the development of
RHF, but in practice, these parameters often
exhibit variable outcomes. Although the best
treatment for RHF is avoidance, when it does
become manifest, a low threshold should be
maintained to promptly start inotropic (ie,
milrinone) and pulmonary vasodilator (ie, ni-
tric oxide) therapy, with a right ventricular
assist device close at hand.
Nicholas C. Dang, MD
Yoshifumi Naka, MD, PhD
Columbia University
College of Physicians and Surgeons
Department of Cardiothoracic Surgery
New York, NY
References
1. Dang NC, Topkara VK, Kim BT, Mercando
ML, Kay J, Naka Y. Clinical outcomes in
patients with chronic congestive heart fail-
ure who undergo left ventricular assist de-
vice implantation. J Thorac Cardiovasc Surg.
2005;130:1302-9.
2. Morgan JA, John R, Rao V, Weinberg AD,
Lee BJ, Mazzeo PA, et al. Bridging to trans-
plant with the HeartMate left ventricular as-
sist device: The Columbia Presbyterian 12-
year experience. J Thorac Cardiovasc Surg.
2004;127:1309-16.
3. Goldstein DJ, Oz MC, Rose EA. Implantable
left ventricular assist devices. N Engl J Med.
1998;339:1522-33.
4. Frazier OH, Rose EA, Macmanus Q, et al.
Multicenter clinical evaluation of the Heart-
Mate 1000 IP left ventricular assist device.
Ann Thorac Surg. 1992;53:1080-90.
doi:10.1016/j.jtcvs.2006.01.014
Apoptosis in ischemic spinal cord
injury
To the Editor:
We read the article of Suzuki and associ-
ates1 titled “Experimental study on the pro-
tective effects of edaravone against isch-
emic spinal cord injury” with great interest.
They studied the effect of a free radical scav-
enger named “edaravone” in a rabbit model
of transient aortic occlusion and claimed its
protective effect on the ischemia-reperfusion
injury of spinal cord by suppressing the level
of reactive oxygen species (ROS). We con-
gratulate Suzuki and associates for their ex-
cellent study. We think that the introduction
of microdialysis method to determine the
production of ROS in the neuronal tissue
after transient ischemia for the first time in
the literature by the authors is a great con-
tribution to our current knowledge.
Recently, data has accumulated that
programmed cell death or apoptosis of mo-
tor neurons in spinal cord after transient
ischemia is an outstanding mechanism of
postoperative paraplegia or paraparesis.2,3
The neuronal injury following transient aortic
occlusion occurs in 2 phases, namely, early
and delayed. Ischemic insult in spinal cord
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